Study Highlights Evidence Gaps in IgA Nephropathy Disease Burden, Treatment Patterns; Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

A recent literature review is calling attention to evidence gaps in IgA nephropathy (IgAN) epidemiology across select Asian Pacific countries.1 The study was published in BMC Nephrology and highlighted a lack of incidence, mortality, treatment pattern, and humanistic burden data in certain countries across the Asia-Pacific region.1 "While geographic variations of IgAN have been studied previously, few recent studies have focused on regional disease burden differences and treatment patterns among IgAN patients across Asian countries/regions and Australia," Kristin Pareja, PharmD, MPH, director of global market access at Otsuka Pharmaceutical US, and colleagues wrote.1 IgAN is the most common form of...